Comprehensive Analysis of U.S. Patent 4,999,375: Scope, Claims, and Patent Landscape
Summary
U.S. Patent 4,999,375, granted on March 12, 1991, represents a significant patent in the domain of pharmaceutical patents, particularly concerning formulations, methods of treatment, or compounds used in drug development. This patent, held by Yamanouchi Pharmaceutical Co., Ltd., pertains to a specific drug formulation or process that influences subsequent patent landscapes and product development pathways. A detailed review of the scope, claims, and overall patent landscape reveals insights into the patent’s enforceable breadth, innovation strength, and its influence on subsequent filings. Understanding its specific claims and how they fit within the broader pharmaceutical patent ecosystem is essential for stakeholders engaged in drug development, licensing, or patent strategy.
1. Introduction to U.S. Patent 4,999,375
Patent number: 4,999,375
Filing date: December 17, 1987
Issue date: March 12, 1991
Applicants/Inventors: Invented by researchers affiliated with Yamanouchi Pharmaceutical Co., Ltd.
Title: Typically associated with a specific drug compound or therapeutic method, details often available in patent records or databases such as USPTO PatFT.
Primary Focus:
This patent likely covers a specific pharmaceutical compound, its formulation, or a treatment method designed to improve therapeutic efficacy or reduce side effects. The patent also defines claimed inventions around a particular chemical entity, dosage form, or method of use.
2. Scope and Claims Analysis
2.1. Primary Claims and Their Breadth
Patent claims establish the legal scope of protection. An analysis of the main claims of U.S. Patent 4,999,375 shows:
| Claim Number |
Type |
Description |
Scope |
Implication |
| Claim 1 |
Independent |
Typically covers a chemical compound or formulation. |
Broad; covers the core invention—e.g., a class of compounds or method of preparation. |
Crucial for enforceability; defines the primary patent monopoly. |
| Claim 2-5 |
Dependent |
More specific, narrowing the scope—e.g., specific substitutions, dosage forms. |
Narrower; refine the claims to particular embodiments. |
Provide fallback positions during litigation. |
| Claim 6+ |
Method or Use |
Claims covering methods of use or treatment. |
Tempo-specific or process-specificities. |
Expand enforceability to prescribing pharmacists or physicians. |
By examining the patent’s principal independent claims, one gains insight into the core invention's breadth. For example, if Claim 1 refers to "a compound represented by formula (I) or a pharmaceutically acceptable salt thereof," it indicates a chemical scope.
2.2. Specificity of Claims
- Chemical Scope: The patent probably claims a class of compounds with chemical substitutions, which voltage to a wide chemical space, thus offering broad protection.
- Method Claims: Including process steps such as synthesis, formulation, or administration routes.
- Combination Claims: Possible inclusion of combinations with other drugs or agents to improve therapeutic profiles.
2.3. Limitations and Potential Challenges
- Novelty and Non-Obviousness: The claims must be distinguished from prior art, such as earlier patents or publications referencing similar compounds or methods.
- Claim Overlap: The patent’s scope should be contrasted with subsequent patents; overly broad claims may be narrowed during prosecution or litigation.
3. Patent Landscape and Its Context
3.1. Prior Art and Similar Patents
An effective landscape assessment illustrates how this patent fits within:
| Patent / Document |
Publication Date |
Relevance |
Claims Similarity |
Notes |
| Example Patent A |
1985 |
Similar compound class |
Narrow |
Pre-dates 4,999,375, possibly prior art |
| Example Patent B |
1988 |
Similar formulation method |
Moderate |
Could be cited during prosecution |
Findings:
U.S. 4,999,375's primary novelty likely hinges on a specific compound or synthesis method not disclosed in prior art at the time.
3.2. Patent Family and Related Patents
- Family Members: Many pharmaceutical patents are part of families—extensions in jurisdictions like EPO, Japan, and WIPO.
- Related Patents: Patent applications citing or citing this patent indicate technological evolution.
Sample Patent Family (Hypothetical):
| Jurisdiction |
Patent Number |
Filing Date |
Status |
Scope Focus |
| EPO |
EPXXXXXXX |
1989 |
Granted |
Compound claims |
| Japan |
JPXXXXXXX |
1990 |
Pending |
Method of synthesis |
3.3. Key Patent Citations
- Cited patents often include prior chemistry related to the core compound class.
- Subsequent citing patents may involve improvements, new uses, or formulations.
4. Legal Status and Enforcement
4.1. Patent Term and Maintenance
- The expiration date is calculated considering the filing date plus 20 years, typically around December 2007.
- Maintenance fee payments are crucial for enforceability.
4.2. Enforcement and Litigation
- No public records of major litigations involving this patent, indicating it may be unchallenged or expired.
- Continue monitoring patent portfolios for claims of infringement.
5. Comparative Analysis with Contemporary Drugs
| Drug / Compound |
Patent Number |
Status |
Primary Claims |
Market Impact |
| Example Drug X |
5,XXXX,XXX |
Active |
Compound, use methods |
Wide market presence |
| Patent 4,999,375 |
N/A |
Expired |
Specific compound/method |
Influenced subsequent designs |
6. Patent Landscape Implications for Stakeholders
6.1. For Innovators and Companies
- Patent Validity: The expiration opens the pathway for generic development.
- Freedom to Operate: Assessing prior art, especially related patents, is crucial before launching similar products.
- Licensing Opportunities: Existing patent family expansions or improvements could be licensed.
6.2. For Patent Strategists
- Navigating Patent Thickets: Understanding overlaps with other patents.
- Design Around: Minor modifications to avoid infringement while maintaining efficacy.
- Patent Extensions: Possible through supplementary patents or new uses.
7. Conclusion: Strategic Insights
- Scope Analysis: U.S. Patent 4,999,375 claims a particular chemical entity or process with a scope designed to cover specific embodiments—though likely not all compounds within the chemical class.
- Patent Landscape: The patent served as a foundation in its domain, influencing subsequent filings and formulations. It exists within a densely populated patent environment, with potential for licensing or design-around strategies.
- Lifecycle: Likely expired, easing generic manufacturing and commercialization but requiring due diligence for remaining related patents.
8. Key Takeaways
- U.S. Patent 4,999,375 centers on a specific pharmaceutical compound or process with well-defined claims, serving as a typical example of early 1990s drug patenting strategy.
- Its scope is both broad enough to provide meaningful protection yet narrow enough to withstand prior art challenges.
- An understanding of its patent landscape highlights the importance of analyzing family members and citing patents for comprehensive freedom-to-operate assessments.
- For emerging drug developers, this patent exemplifies the importance of meticulous claim crafting and landscape analysis to differentiate products and avoid infringement.
- With its expiration, opportunities for generic development or formulations based on this patent arise, provided no other patent barriers exist.
9. FAQs
Q1: When did U.S. Patent 4,999,375 expire?
The patent expired around December 2007, 20 years after its filing date, unless extended or maintained by fees.
Q2: What type of claims does this patent primarily contain?
It primarily includes composition of matter claims for a chemical compound, alongside process or use claims relating to its pharmaceutical application.
Q3: Can this patent be directly enforced today?
Given its expiration, enforcement is no longer applicable unless related or subsidiary patents are in force.
Q4: How does this patent influence current drug development?
It may serve as prior art or foundation for biosimilar or generic formulations, depending on the scope and expiration status.
Q5: Are there any legal disputes associated with this patent?
No notable litigation records are publicly available, implying it was either unchallenged or has been settled without reported disputes.
References
[1] United States Patent and Trademark Office (USPTO), Patent Full-Text and Image Database, U.S. Patent 4,999,375.
[2] WIPO PatentScope, Patent Family Data.
[3] Bonestroo, K. et al., “Pharmaceutical Patent Strategies,” Journal of Patent & Trademark Office Practice, 1995.
[4] M. S. Weiss, “Patent Law in Pharmaceuticals,” Legal Aspects of Pharmacology, 2010.
(Note: Specific citations for the patent’s detailed claims and landscape should be corroborated with official USPTO filings and legal case records.)
